Glaxo Pays $175 Million To Settle Antitrust Suit Over Relafen Patent

Law360, New York (February 7, 2004, 12:00 AM EST) -- GlaxoSmithKline has agreed to pay $175 million to settle a lawsuit alleging that the company had violated U.S. antitrust law by blocking generic versions of its Relafen arthritis medicine.

The U.K. drug maker, the largest in Europe, said the settlement is being submitted for review Friday to the U.S. District Court for the District of Massachusetts, where the case has been pending since 2001.

Consumers, health plans and pharmacies have sued drug companies on allegations that they misused patents to block low-cost alternatives to their medicines....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.